James S. Economou

James S. Economou's AcademicInfluence.com Rankings

James S. Economou

Philosophy

#10678

World Rank

#14649

Historical Rank

Logic

#7716

World Rank

#9559

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is James S. Economou Influential?

(Suggest an Edit or Addition)

According to Wikipedia, James S. Economou is an American physician-scientist on the faculty of the University of California, Los Angeles where he is also a surgical oncologist and tumor immunologist. He was Vice Chancellor for Research at UCLA where he promoted academic entrepreneurship, transdisciplinary research, and support of the humanities, arts, and social sciences. The UCLA research enterprise generates almost one billion dollars in extramural funds annually.

(See a Problem?)

James S. Economou's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Technical details of intraoperative lymphatic mapping for early stage melanoma. (1992) (4291)
IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. (1989) (422)
A comparison of gene transfer methods in human dendritic cells. (1997) (333)
Radiation enhances regulatory T cell representation. (2011) (319)
Current developments in cancer vaccines and cellular immunotherapy. (2003) (300)
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. (2003) (267)
The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. (1992) (226)
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (204)
Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. (1997) (194)
A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides (2006) (184)
Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma (2014) (183)
Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. (1999) (170)
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. (2003) (166)
Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. (1998) (164)
Production of Interleukin-1 and Tumor Necrosis Factor by Human Peripheral Monocytes Activated by Periodontal Bacteria and Extracted Lipopolysaccharides (1988) (143)
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. (2009) (139)
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans (2011) (139)
Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion (1986) (133)
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. (2006) (133)
α-Fetoprotein-specific Genetic Immunotherapy for Hepatocellular Carcinoma (1999) (133)
Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. (2000) (127)
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade (2009) (123)
Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran (1998) (120)
T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human α Fetoprotein1 (2001) (120)
Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma (2008) (119)
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. (2013) (119)
Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy (2004) (118)
Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. (1992) (116)
Ionizing Radiation Affects Human MART-1 Melanoma Antigen Processing and Presentation by Dendritic Cells1 (2004) (114)
Determinant spreading and tumor responses after peptide-based cancer immunotherapy. (2003) (112)
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. (2018) (110)
Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line (1989) (109)
p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. (1999) (106)
Nuclear magnetic resonance studies of cancer. IV. Correlation of water content with tissue relaxation times. (1974) (105)
alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. (2001) (103)
In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. (1996) (97)
Nuclear magnetic resonance studies of several experimental and human malignant tumors. (1973) (94)
Management of primary germ cell tumors of the mediastinum. (1982) (93)
Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. (1998) (89)
Cancer immunotherapy using gene-modified dendritic cells. (2002) (87)
In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. (1997) (86)
Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. (1999) (83)
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. (2001) (81)
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma (2008) (79)
Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. (2000) (75)
Human gene marker/therapy clinical protocols. (1996) (73)
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. (1996) (70)
Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1 (2006) (67)
Human Dendritic Cell Maturation by Adenovirus Transduction Enhances Tumor Antigen-Specific T-Cell Responses (2004) (66)
Lymphocyte-activating factor. I. Generation and physicochemical characterization. (1978) (66)
NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain1 (2006) (65)
Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer (2007) (64)
Tumour necrosis factor production by IL-2-activated macrophages in vitro and in vivo. (1989) (59)
Interleukin‐4 Downregulates Interleukin‐6 Production in Human Peripheral Blood Mononuclear Cells (1990) (57)
Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. (2000) (56)
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. (2010) (54)
Identification and characterization of a low-affinity granulocyte-macrophage colony-stimulating factor receptor on primary and cultured human melanoma cells. (1991) (54)
Human gene marker/therapy clinical protocols. (1999) (51)
CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. (2001) (51)
Immunomodulation by imiquimod in patients with high-risk primary melanoma (2011) (51)
Stereotactic delivery of a recombinant adenovirus into a C6 glioma cell line in a rat brain tumor model. (1994) (50)
Nuclear magnetic resonance studies of cancer. V. Appearance and development of a tumor systemic effect in serum and tissues. (1974) (50)
Interleukin‐4 inhibits the expression of tumour necrosis factors α and β, interleukins‐1 β and ‐6 and interferon‐γ (1995) (49)
CD4+CD25− T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model1 (2008) (47)
Influences of interleukins 2 and 4 on tumor necrosis factor production by murine mononuclear phagocytes. (1990) (47)
Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells (1999) (44)
Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. (2013) (44)
Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients (2014) (44)
RETROVIRAL‐MEDIATED GENE TRANSFER INTO RAT EXPERIMENTAL LIVER TRANSPLANT (1994) (44)
Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. (2000) (43)
Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays (2006) (43)
Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7. (1995) (40)
Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. (2003) (38)
Adenovirus-mediated p53 gene delivery potentiates the radiation-induced growth inhibition of experimental brain tumors (1998) (37)
Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. (2000) (37)
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. (2011) (35)
Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. (1998) (34)
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells (2005) (34)
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy (2012) (32)
Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. (1997) (31)
Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. (2014) (31)
Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. (1996) (29)
Antibody-mediated suppression of grafted lymphoma. IV. Influence of time of tumor residency in vivo and tumor size upon the effectiveness of suppression by syngeneic antibody (1976) (29)
Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells1 (2004) (28)
Actinobacillus actinomycetemcomitans and Bacteroides gingivalis activate human peripheral monocytes to produce interleukin-1 and tumor necrosis factor. (1988) (27)
Interleukin‐1 and tumor necrosis factor production by tumor‐associated mononuclear leukocytes and peripheral mononuclear leukocytes in cancer patients (1988) (27)
Genetic immunotherapy for cancer. (2000) (27)
Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4 Differentially Regulate the Human Tumor Necrosis Factor-α Promoter Region (1995) (27)
Interleukin-3 in gene therapy of cancer. (1994) (27)
Bone Marrow Transplantation in Cancer Therapy: Inactivation by Antibody and Complement of Tumor Cells in Mouse Syngeneic Marrow Transplants 1 (1978) (25)
Overview of biological response modifiers. (1989) (25)
Immunosensitization of Melanoma Tumor Cells to Non-MHC Fas-Mediated Killing by MART-1-Specific CTL Cultures1 (2001) (24)
Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. (1999) (23)
Mechanisms of Tumor Immunity: the Role of Antibody and Nonimmune Effectors1 (1978) (22)
Soft tissue sarcomas of the extremity and retroperitoneum: advances in management. (1991) (22)
Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway (2014) (22)
Antigen presentation by MART‐1 adenovirus‐transduced interleukin‐10‐polarized human monocyte‐derived dendritic cells (2004) (21)
Interleukin-6 production by human melanoma cell lines. (1992) (21)
Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. (2007) (18)
TNF-α and IFN-γ reverse IL-4 inhibition of lymphokine-activated killer cell function (1990) (18)
Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. (2009) (18)
Cytokine-mediated gene therapy for cancer (1994) (17)
The effects of cytokine gene transfer into tumors on host cell infiltration and regression. (1996) (16)
Modification of tumor microenvironment by cytokine gene transfer. (1995) (15)
Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene–modified dendritic cell vaccines (2002) (15)
Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: Correlation with clinical toxicity (2005) (15)
Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs (2012) (15)
Immunotherapy of cancer with antibody. (1976) (15)
Mechanisms of tumor immunity: the role of antibody and nonimmune effectors. (1978) (15)
The adenoviral transcription factor, E1A 13S, trans-activates the human tumor necrosis factor-alpha promoter. (1996) (14)
Prognostic significance of melanoma arising in the scalp. (1988) (13)
Soft tissue sarcomas. (2004) (12)
Interleukin-4 inhibits the expression of tumour necrosis factors alpha and beta, interleukins-1 beta and -6 and interferon-gamma. (1995) (12)
Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. (1991) (12)
Differential effects of granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor on tumor necrosis factor and interleukin-1 production in human monocytes. (1990) (10)
NK and CD 4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain 1 (2006) (10)
Human gene marker/therapy clinical protocols. (1997) (9)
Granulocyte-macrophage colony-stimulating factor and interleukin-4 differentially regulate the human tumor necrosis factor-alpha promoter region. (1995) (8)
Broad antitumor protection by dendritic cells administered to CD8α knock out mice (2006) (8)
Interleukin 32 expression in human melanoma (2019) (8)
T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3 (2011) (7)
Observations on a possible association between the acid mucopolysaccharides and lysozyme (1971) (7)
Detection of malignancy by nuclear magnetic resonance. (1973) (7)
Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-Dioxygenase (IDO) Expression With the CTLA4 Blocking MAB CP-675,206 (2006) (6)
Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab. (2006) (6)
Gender bias in biomedical research. (2014) (6)
Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. (2004) (6)
TUMOR-DIRECTED CYTOKINE GENE THERAPY (1994) (5)
Selective and Nonselective Replication of an E 1 B-deleted Adenovirus in Hepatocellular Carcinoma 1 (1999) (4)
TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function. (1990) (4)
Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma (2010) (3)
IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. (1993) (3)
Acquired resistance to T cell adoptive transfer by inflammation-induced melanoma dedifferentiation. (2018) (3)
Molecular mechanisms of interleukin 2 induction of tumor necrosis factor gene expression in macrophages (1988) (3)
Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products (2018) (3)
Function in a Human Melanoma Model MHC Class I-Restricted Cytolytic Effector TCR Synthesize Th 1 Cytokines and Exhibit MHC Class I-Restricted Epitope-Specific T Cells Transduced to Express − CD 25 + CD 4 Baltimore and Bijay Mukherji (2008) (3)
Mechanisms of Tumor Immunity: the Role of Antibody and Nonimmune Effectors (Part 2 of 3) (1978) (3)
Current Deve lopments in Cancer Vacc ines and Cel lu lar Immunotherapy (2003) (2)
Macrophage shortage within tumor diminishes effectiveness of igg1 antibody-mediated suppression. Abstr. (1977) (2)
Preclinical Development Proteasome Inhibition Blocks NFk B and ERK 1 / 2 Pathways , Restores Antigen Expression , and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs (2012) (2)
Interleukin-4: A potent inhibitor of IL-6, TNF-α, IFN-γ, and IL-1β production (1990) (2)
Interleukin-2-responsive wound-infiltrating lymphocytes in surgical adjuvant cancer immunotherapy. (1993) (2)
Transduction of murine and human tumors using recombinant adenovirus vectors (2006) (2)
Engines of Discovery and Innovation. (2016) (2)
A Society in Transition: Presidential Remarks at the 65th Annual SSO Cancer Symposium (2012) (1)
Therapy of a murine lymphoma with tumor-specific antiserum in combination with adriamycin, cyclophosphamide, or L-asparaginase. (1980) (1)
Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients (2014) (1)
A Histone Deacetylase Inhibitor (HDACI) Sensitizes B16 Melanoma to Adoptive Transfer (AT) Immunotherapy (2006) (1)
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy (2012) (1)
Lymphocyte-Activating Factor (1978) (1)
The role of antibody in tumor immunity. (1981) (1)
Cytokine Regulation of the Induction of Cytotoxic Effector Cells by IL-2 (1990) (1)
A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy. (2004) (1)
Abstract C143: Overcoming melanoma dual resistance to Vemurafenib and adoptive immunotherapy by chromatin remodeling drug. (2013) (0)
Forthcoming papers (2004) (0)
Abstract 1928: Resistance of human melanoma to MART-1/HLA A2.1 specific CTL (F5 CTL)-killing: poor recognition, low MART-1 expression and reversal of resistance (2010) (0)
T Cell Responses to Alpha Fetoprotein-Derived Immunodominant Peptide-Pulsed Dendritic Cells in Patients with Hepatocellular Cancer (2004) (0)
DENDRITIC CELLS AND VACCINES Treatment ofMetastatic Colorectal Cancer Patients with a Tumor Lysate Pulsed Dendritic Cell Vaccine: A Randomized Evaluation of Ex Vivo CD40L Activation (2004) (0)
The status of gene therapy for surgical disease. (2002) (0)
cultured human melanoma cells macrophage colony-stimulating factor receptor on primary and Identification and characterization of a low-affinity granulocyte (2003) (0)
New immunobiologic approaches to the control of cancer. (1989) (0)
Comparison of a combined MHC tetramer and interferon-γ (IFN-γ) intracellular cytokine staining (ICS) assay with individual MHC-tetramer and IFN-γ ELISPOT assays to monitor cancer immunotherapy (2007) (0)
TCR transgenic and patient-derived CTL killing of CTL-resistant melanoma: modulation of TRAIL apoptotic pathway and immune sensitization by epigenetic modifier SAHA (TUM2P.901) (2014) (0)
Human gene marker/therapy clinical protocols. (1996) (0)
35. Melanoma clinical trials in the United States (2012) (0)
Tumor Immunology and Immunotherapy (2012) (0)
Tumournecrosis factor production byIL-2-activated macrophages invitro andinvivo (1989) (0)
Adoptively transferred TCR-engineered cytotoxic human T lymphocytes use TRAIL apoptotic pathway in killing melanomas: Pivotal role of DR5 and regulation of resistance by SAHA (P2124) (2013) (0)
Tumor Antigen-Specific T Cell Responses in Hepatocellular Cancer Patients (2006) (0)
Abstract 4839: Adoptive cell transfer of transgenic T cells elicited a two-wave antitumor cellular immune response consisted of engineered and endogenous T lymphocytes with different sets of functions (2012) (0)
Human gene marker/therapy clinical protocols. (2000) (0)
Abstract 2684: Immunosensitization of apoptosis-resistant MART-1 negative human melanomas by bortezomib (2011) (0)
Interleukin 32 expression in human melanoma (2019) (0)
T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp 3 (2011) (0)
In the Next Issue - Online Only. (2016) (0)
Abstract B292: HDACi immunosensitizes CTL-resistant human melanomas to adoptive cell transfer (ACT) by modulating TRAIL/DR5apoptotic pathway. (2013) (0)
Current D evelopments i n C ancer V accines a nd Cellular I mmunotherapy (2003) (0)
Mechanisms of Tumor Immunity: the Role of Antibody and Nonimmune Effectors (Part 3 of 3) (1978) (0)
Adenovirus Lymphocytes by Dendritic Cells Transduced Generation of Melanoma-Specific Cytotoxic T (1998) (0)
OR.96. MHC Class I-Restricted Human Melanoma Epitope Specific TCR Engineered Human CD4 T Cells Exhibit Anti-Tumor Effector Function, Proliferate upon Cognate Stimulation, Amplify CD8+CTL Generation, and Mitigate Inducible T Regulatory Cell (iTreg) Activities in Human Melanoma, in vitro (2009) (0)
Abstract 1925: MHC class I-restricted MART-127-35 specific TCR engineered human CD4+ and CD8+ T cells exhibit polyfunctional properties (2010) (0)
One of the Most Important Phone Calls of My Career. (2021) (0)
Antiserum-complement treatment of tumor-contaminated syngeneic mouse bone marrow transplants. Abstr. (1977) (0)
Cancer Research in the 21st Century. (2016) (0)
Cancer Therapy: Clinical Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma (2009) (0)
B4. Nitric oxide suppresses the expression of the tolerogenic transcription factor FOXP3 in tumor cells (2007) (0)
Genetic analysis of human tumor necrosis factor-α promoter function in human tumor-infiltrating lymphocytes and other cell types (1989) (0)
Characterization of Melanoma Antigen-Specific T Cells in a Long Term Survivor with Metastatic Melanoma with a Stable Peripheral Blood Population of Greater Than 5% of MART-1-Specific CD8+ T Cells (2004) (0)
Standardization of MHC Tetramer and ELISPOT Assays To Quantitate Antigen-Specific T Cell Expansion after CTLA4 Blockade (2004) (0)
PRESIDENTIAL FORUM Cancer Research in the 21st Century (2016) (0)
Engineering antigen-specific T cells for in vivo imaging: A study of the dynamic biological interactions in anti-tumor immunity (2007) (0)
Sensitization of BRAFi- and immune- dual resistant melanomas to immune effector cells through HDACi-mediated regulation of apoptotic machinery (TUM7P.940) (2014) (0)
Human gene marker/therapy clinical protocols. (1999) (0)
Cells in the Absence of CD8-Positive Cells Enhanced Tumor Responses to Dendritic (2013) (0)

This paper list is powered by the following services:

Other Resources About James S. Economou

en.wikipedia.org

What Schools Are Affiliated With James S. Economou?

James S. Economou is affiliated with the following schools: